LEXICON PHARMACEUTICALS, INC. (LXRX)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Address

2445 TECHNOLOGY FOREST BLVD.
THE WOODLANDS, TX 77381

Founded

1995

Number of Employees

285

Website

http://www.lexpharma.com

Buyback

Buyback Data 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
$ Amount Purchased
($ in 000s )		 $887 $358 $621 $1,679 - $941 $1,026 $2,675 $864 $824 $1,729 $1,160
Average Price $13.28 $6.58 $9.07 $16.45 - $5.51 $2.66 $7.19 $2.85 $2.17 $2.62 $4.53
# Shares Purchased 66,737 54,351 68,482 102,052 - 170,806 385,758 372,040 303,201 379,768 660,039 256,323
Buyback Performance 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
Total Return to Date -92.5% -84.8% -89.0% -93.9% - -81.9% -62.4% -86.1% -64.9% -53.9% -61.8% -77.9%
S&P 500 Return to Date 181.9% 173.0% 168.6% 129.7% - 93.1% 74.8% 31.7% 37.3% 31.3% 7.4% 92.9%
Excess Total Return -274.3% -257.8% -257.6% -223.6% - -175.0% -137.2% -117.7% -102.2% -85.3% -69.2% -170.8%
Quartile Rank
Percentile Rank 2% 4% 3% 1% - 3% 6% 2% 7% 6% 1% 5%
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed
WESTEND SA

Scholar Rock Holding Corp
Vanda Pharmaceuticals Inc.
INVUS, L.P.

LEXICON PHARMACEUTICALS, INC.
RIGEL PHARMACEUTICALS INC